Benign fabrication of microfluidic hydrogel for improved artificial vasculature in bone implants. We will create a benign technology for synthesising microfluidic hydrogels to generate artificial vascultures in bone implants. It is a critical step to enable the use of tissue-engineered vital organs, such as bone, heart and kidney in patients with end-stage organ failure. Thicker scaffolds will be possible, as the vasculature will provide nutrients and oxygen for cells to grow into 3D scaffolds. ....Benign fabrication of microfluidic hydrogel for improved artificial vasculature in bone implants. We will create a benign technology for synthesising microfluidic hydrogels to generate artificial vascultures in bone implants. It is a critical step to enable the use of tissue-engineered vital organs, such as bone, heart and kidney in patients with end-stage organ failure. Thicker scaffolds will be possible, as the vasculature will provide nutrients and oxygen for cells to grow into 3D scaffolds. It will promote capacity of Australia for manufacturing global biomaterial products for tissue engineering. We will also develop in-situ imaging analytical protocols for the rapid analysis of broad arrays of functional molecules, with significant bearing on BioMEMS design to develop methods for diagnosis of fatal diseases.Read moreRead less
Biomaterial applications of synthetic elastin. The grant will develop a new collaboration between two established laboratories. The Weiss Lab (synthetic elastin; University of Sydney, Australia) will send elastin materials to the Langer Lab (interface of biotechnology and materials science; MIT, USA). Prof. Weiss will visit the Langer Lab and be trained in and participate collaboratively in the use of established MIT methodologies that will focus on applications in cardiac tissue engineering, co ....Biomaterial applications of synthetic elastin. The grant will develop a new collaboration between two established laboratories. The Weiss Lab (synthetic elastin; University of Sydney, Australia) will send elastin materials to the Langer Lab (interface of biotechnology and materials science; MIT, USA). Prof. Weiss will visit the Langer Lab and be trained in and participate collaboratively in the use of established MIT methodologies that will focus on applications in cardiac tissue engineering, controlled release of drugs and vocal fold repair. The MIT group will benefit from access to and the use of elastin materials that are developed in AustraliaRead moreRead less
Single-session Introduction of Mutations in Parallel Lines (SIMPL). This project aims to develop a novel method for markedly accelerating production of genetically modified mice, which are a key 'tool' for studying biological processes and diseases. The work plans to take CRISPR, the latest gene-editing technique, to the next level by developing a novel CRISPR-based method to generate different mouse strains with distinct variations of the same gene sequences, at a fraction of the present cost a ....Single-session Introduction of Mutations in Parallel Lines (SIMPL). This project aims to develop a novel method for markedly accelerating production of genetically modified mice, which are a key 'tool' for studying biological processes and diseases. The work plans to take CRISPR, the latest gene-editing technique, to the next level by developing a novel CRISPR-based method to generate different mouse strains with distinct variations of the same gene sequences, at a fraction of the present cost and time. This project should overcome a major barrier to studying gene function with unprecedented detail, thereby opening new avenues for future research into biological processes. Thus, the outcomes from this project should impact on the entire field of biomedical research, and advance Australia's biotech industry.Read moreRead less